Episode Details
Back to EpisodesNicotinamide/B3 gets surprisingly strong human glaucoma evidence
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/nicotinamide-b3-gets-surprisingly-strong-human-glaucoma-evidence
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Nicotinamide/B3 Gets Surprisingly Strong Human Glaucoma Evidence What the 2026 studies show about vitamin B3, nicotinamide, glaucoma prevention, neuroprotection, dosage and safety Introduction As of August 13, 2026, the evidence linking nicotinamide, a form of vitamin B3, with glaucoma protection has become substantially more persuasive—but it still has not crossed the threshold required to change routine treatment. Two new human studies are driving the renewed interest: A July 9, 2026, JAMA Ophthalmology cohort study found that patients with ocular hypertension who had documented systemic nicotinamide exposure were much less likely to receive a later diagnosis of primary open-angle glaucoma. An August 2026 American Journal of Ophthalmology analysis of the Rotterdam Study found that higher dietary intake of niacin, the broader vitamin B3 category, and vitamin B12 was associated with a lower risk of developing open-angle glaucoma. These findings reinforce earlier randomized trials showing that nicotinamide may improve certain measures of retinal function in people who already have glaucoma. They also fit a biologically plausible theory: aging, elevated eye pressure and oxidative stress may deplete nicotinamide adenine dinucleotide, or NAD+, leaving retinal ganglion cells less able to produce energy and survive stress. However, the most dramatic prevention result is observational, not randomized. High-dose nicotinamide also carries a real—although probably uncommon—risk of liver injury. The evidence is promising enough to justify large clinical trials, but not yet strong enough to replace pressure-lowering treatment or support unsupervised high-dose supplementation. () The central new finding: lower glaucoma conversion in ocular hypertension What the JAMA Ophthalmology study examined The study used deidentified electronic health-record data from 67 United States health care organizations, covering March 2006 through March 2026. Researchers identified people with ocular hypertension but no previous open-angle glaucoma, laser treatment or glaucoma eye-drop therapy. The analysis compared: 1,460 patients with documented systemic nicotinamide exposure 1,460 propensity-matched control patients with no recorded use of nicotinamide or niacin The groups were followed for an average of 3.7 years. The study was published online on July 9, 2026. () Primary open-angle glaucoma diagnosis A subsequent diagnosis of primary open-angle glaucoma occurred in: For the full table, please open this article on visualfieldtest.com. The reported hazard ratio of 0.34 corresponds to approximately a 66% lower hazard of diagnosis during follow-up. The absolute difference was 5.5 percentage points, with a 95% confidence interval of 3.8 to 7.3 percentage points. If the association were causal, a simple calculation would suggest that roughly 18 similar ocular-hypertension patients would need to receive nicotinamide to prevent one additional diagnosis over approximately four years. That number was not reported by the investigators and should not be interpreted as a treatment recommendation. () Fewer glaucoma treatments and laser procedures The study also found lower rates of treatment escalation: Topical eye-pressure-lowering treatment: 13.6% with nicotinamide versus 21.2% in controls Hazard ratio: 0.57 Laser trabeculoplasty: 0.8% with nicotinamide versus 1.9